Drug Profile
Research programme: human metapneumovirus/parainfluenza virus vaccine - AstraZeneca
Alternative Names: MEDI-536Latest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AstraZeneca
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Metapneumovirus infections; Parainfluenza virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Metapneumovirus-infections in USA (Intranasal)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Parainfluenza-virus-infections in USA (Intranasal)
- 26 Jul 2007 Preclinical trials in Metapneumovirus-infections in USA (Intranasal)